Evaluating the feasibility of integrating salivary testing for congenital CMV into the Newborn Hearing Screening Programme in the UK

Kadambari, Seilesh; Luck, Suzanne; Davis, Adrian; Walter, Simone; Ågrup, Charlotte; Atkinson, Claire; Stimson, Laura; Williams, Eleri; Berrington, Janet; Griffiths, Paul

doi:10.1007/s00431-015-2506-8

Cited by 25 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…39 The feasibility of integrating congenital CMV screening into the UNHS program has been illustrated in a recent study conducted in the United Kingdom. 40 Another pilot study is currently underway at our hospital to explore the feasibility and long-term cost-effectiveness of a comprehensive newborn screening program comprising simultaneous hearing, genetic, and CMV screenings at birth.…”

Section: Discussionmentioning

confidence: 99%

Newborn genetic screening for hearing impairment: a population-based longitudinal study

Tsai

Hung

et al. 2017

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Newborn genetic screening for hearing impairment: a population-based longitudinal study

Tsai

Hung

et al. 2017

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

“…They reported that 98% of the study population provided a salivary swab within the 3-week period. Kadambari et al 13 included an assessment of the feasibility of introducing targeted screening within the UK, and all healthcare professional involved agreed it was feasible to introduce a screening programme. Diener et al 22 evaluated the success of a targeted cCMV screening programme and found that with the introduction of targeted cCMV screening, timely diagnostic hearing evaluation rates improved, from 56% to 77%.…”

Section: Discussionmentioning

confidence: 99%

“…The study reported that 98% of the study population successfully provided a salivary swab within the 3-week period. Kadambari et al 13 included an assessment of the feasibility of introducing targeted screening within the UK, and all healthcare professional involved agreed it was feasible to introduce a targeted screening programme. The acceptability of either targeted or universal screening for CMV to families would need to be addressed during the development of potential programmes.…”

Section: Introductionmentioning

confidence: 99%

Does screening for congenital cytomegalovirus at birth improve longer term hearing outcomes?

et al. 2018

View full text Add to dashboard Cite

Currently, the diagnosis of congenital cytomegalovirus (cCMV) infection in most highly resourced countries is based on clinical suspicion alone. This means only a small proportion of cCMV infections are diagnosed. Identification, through either universal or targeted screening of asymptomatic newborns with cCMV, who would previously have gone undiagnosed, would allow for potential early treatment with antiviral therapy, ongoing audiological surveillance and early intervention if sensorineural hearing loss (SNHL) is identified. This paper systematically reviews published papers examining the potential benefits of targeted and universal screening for newborn infants with cCMV. We found that the treatment of these infants with antiviral therapy remains controversial, and clinical trials are currently underway to provide further answers. The potential benefit of earlier identification and intervention (eg, amplification and speech therapy) of children at risk of later-onset SNHL identified through universal screening is, however, clearer.

show abstract

“…Change in avidity may also be used to predict timing of infection 13 . Maternal CMV viraemia using polymerase chain reaction (PCR) may be also useful to establish the time of infection 14 .…”

mentioning

confidence: 99%

The obstetrician, congenital cytomegalovirus, clinical and diagnostic approaches to the pregnant woman

Shand¹

2015

Microbiol. Aust.

View full text Add to dashboard Cite

There is low awareness of congenital cytomegalovirus (CMV) in Australia. Routine pregnancy serological screening for CMV is not recommended, but all pregnant women should be given advice about CMV prevention. Obstetricians may be asked to see a pregnant woman when serology suggests CMV infection or when features of fetal infection are present on ultrasound. If maternal CMV infection is confirmed, the timing of infection (pre-pregnancy or gestation of pregnancy), must be determined to predict the fetal risks. In addition, it is important to establish whether maternal infection is primary or reactivation. If there is fetal infection, ultrasound can be used to attempt to establish whether the fetus may have been affected. Serial serology, CMV IgG avidity, maternal viraemia (using serum PCR), amniotic fluid CMV PCR, serial fetal ultrasounds, and possibly fetal MRI (magnetic resonance imaging) are investigations that may be useful to predict neonatal outcomes. Timely and accurate counselling is important to optimise maternal and neonatal management.

show abstract

Evaluating the feasibility of integrating salivary testing for congenital CMV into the Newborn Hearing Screening Programme in the UK

Abstract: It is feasible for hearing screeners to obtain saliva swabs to test for CMV DNA using real-time PCR in newborns referred after their initial hearing screen. Rapid diagnostic testing for cCMV needs a more detailed clinical and cost-effectiveness analysis.

Cited by 25 publications

References 11 publications

Newborn genetic screening for hearing impairment: a population-based longitudinal study

Newborn genetic screening for hearing impairment: a population-based longitudinal study

Does screening for congenital cytomegalovirus at birth improve longer term hearing outcomes?

The obstetrician, congenital cytomegalovirus, clinical and diagnostic approaches to the pregnant woman

Contact Info

Product

Resources

About